Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

被引：94

作者：

Loi, Sherene ^{[1
,2
]}

机构：

[1] Peter MacCallum Canc Ctr, Translat Breast Canc Genom Lab, Canc Therapeut Program, East Melbourne, Vic, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia

来源：

ONCOIMMUNOLOGY | 2013年 / 2卷 / 07期

关键词：

breast cancer; immunotherapies; biomarkers; tumor infiltrating lymphocytes; prognosis; trastuzumab efficacy; MICROENVIRONMENT; ADJUVANT;

D O I：

10.4161/onci.24720

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

By analyzing over 2000 samples from a randomized clinical trial, we have recently associated high levels of tumor-infiltrating lymphocytes with an excellent prognosis among triple negative breast cancer patients as well with improved clinical responses to immunogenic chemotherapy among patients bearing HER2 over-expression. These findings suggest that immunomodulation could represent a new approach to treat these aggressive breast cancer subtypes.

引用

页数：3

共 10 条

[1] LYMPHOCYTE INFILTRATES AS A PROGNOSTIC VARIABLE IN FEMALE BREAST-CANCER [J].

AALTOMAA, S ;

LIPPONEN, P ;

ESKELINEN, M ;

KOSMA, VM ;

MARIN, S ;

ALHAVA, E ;

SYRJANEN, K .

EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :859-864

[2] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].

Clynes, RA ;

Towers, TL ;

Presta, LG ;

Ravetch, JV .

NATURE MEDICINE, 2000, 6 (04) :443-446

[3] Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer [J].

Denkert, Carsten ;

Loibl, Sibylle ;

Noske, Aurelia ;

Roller, Marc ;

Mueller, Berit Maria ;

Komor, Martina ;

Budczies, Jan ;

Darb-Esfahani, Silvia ;

Kronenwett, Ralf ;

Hanusch, Claus ;

von Toerne, Christian ;

Weichert, Wilko ;

Engels, Knut ;

Solbach, Christine ;

Schrader, Iris ;

Dietel, Manfred ;

von Minckwitz, Gunter .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :105-113

[4] Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial [J].

Joensuu, Heikki ;

Bono, Petri ;

Kataja, Vesa ;

Alanko, Tuomo ;

Kokko, Riitta ;

Asola, Raija ;

Utriainen, Tapio ;

Turpeenniemi-Hujanen, Taina ;

Jyrkkio, Sirkku ;

Moykkynen, Kari ;

Helle, Leena ;

Ingalsuo, Seija ;

Pajunen, Marjo ;

Huusko, Mauri ;

Salminen, Tapio ;

Auvinen, Paivi ;

Leinonen, Hannu ;

Leinonen, Mika ;

Isola, Jorma ;

Kellokumpu-Lehtinen, Pirkko-Liisa .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5685-5692

[5] Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity [J].

Kang, Tae Heung ;

Mao, Chih-Ping ;

Lee, Sung Yong ;

Chen, Alexander ;

Lee, Ji-Hyun ;

Kim, Tae Woo ;

Alvarez, Ronald D. ;

Roden, Richard B. S. ;

Pardoll, Drew ;

Hung, Chien-Fu ;

Wu, T. -C. .

CANCER RESEARCH, 2013, 73 (08) :2493-2504

[6]

Loi S, 2012, J CLIN ONCOL, V30

[7] Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 [J].

Loi, Sherene ;

Sirtaine, Nicolas ;

Piette, Fanny ;

Salgado, Roberto ;

Viale, Giuseppe ;

Van Eenoo, Francoise ;

Rouas, Ghizlane ;

Francis, Prudence ;

Crown, John P. A. ;

Hitre, Erika ;

de Azambuja, Evandro ;

Quinaux, Emmanuel ;

Di Leo, Angelo ;

Michiels, Stefan ;

Piccart, Martine J. ;

Sotiriou, Christos .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) :860-867

[8] CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation [J].

Rakhra, Kavya ;

Bachireddy, Pavan ;

Zabuawala, Tahera ;

Zeiser, Robert ;

Xu, Liwen ;

Kopelman, Andrew ;

Fan, Alice C. ;

Yang, Qiwei ;

Braunstein, Lior ;

Crosby, Erika ;

Ryeom, Sandra ;

Felsher, Dean W. .

CANCER CELL, 2010, 18 (05) :485-498

[9] Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers [J].

Simon, Richard M. ;

Paik, Soonmyung ;

Hayes, Daniel F. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (21) :1446-1452

[10] Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy [J].

Stagg, John ;

Loi, Sherene ;

Divisekera, Upulie ;

Ngiow, Shin Foong ;

Duret, Helene ;

Yagita, Hideo ;

Teng, Michele W. ;

Smyth, Mark J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (17) :7142-7147

← 1 →